CD79A and cranioectodermal dysplasia: Second, by adding DGP-IgG to the mass screening protocol, we found that the performance of TTG-IgA has improved marginally as DGP-IgG could rarely recognize CeD patients that TTG-IgA has missed; this finding is in agreement with several studies that showed that anti-DGP antibodies identified CeD patients negative for TTG-IgA (10–13).